BiVictriX Therapeutics
Latest round
- Seed
Last raised
- Jul 2019
Total raised
- $0.4M
Investors
- 2
About BiVictriX Therapeutics
BiVictriX Therapeutics Ltd.Founded in 2016, BiVictriX Therapeutics Ltd. is based in Cheshire, UK, and specializes in cancer therapeutic development.BiVictriX is primarily focused on developing next-generation cancer therapeutics through its proprietary Bi-Cygni® platform. This innovative approach aims to 'un-mask' cancer cells, making them visible and vulnerable to targeted therapies. The core offerings include antibody-drug conjugates (ADCs) that effectively combine the selective targeting capability of antibodies with the potent efficacy of chemotherapy agents. These ADCs are engineered to release their cytotoxic components only upon binding to specific targets on the cancer cell surface, thereby reducing harm to healthy cells. The company's products are designed to address some of the most aggressive cancers, enhancing the precision of cancer treatments.BiVictriX generates revenue through partnerships with healthcare providers, pharmaceutical companies, and research institutions focused on oncology. The revenue model typically involves collaborations and licensing agreements, wherein clients access the Bi-Cygni® platform for the development of tailored cancer therapies. These transactions are structured around significant milestones, such as preclinical and clinical trial advancements, which may involve upfront payments and royalties on future sales of the products developed. The company's flagship offering, the Bi-Cygni® ADCs, is positioned to enter the market through strategic partnerships, enabling broader distribution among hospitals and clinics specializing in cancer treatment. Through these collaborations, BiVictriX aims to not only enhance treatment options but also ensure that clinicians can administer more effective doses while minimizing side effects for patients.BiVictriX Therapeutics Ltd. The company is focused on the ongoing development and launch of new cancer therapeutics designed through its Bi-Cygni® platform. BiVictriX aims to expand its presence in North America and Europe, targeting healthcare providers and institutions by the end of 2024.
Who invested in BiVictriX Therapeutics
2 investors across 1 round
See all investors in BiVictriX Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 30, 2019
Amount
$0.4M
Investors
Questions about BiVictriX Therapeutics
Who invested in BiVictriX Therapeutics?
BiVictriX Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BiVictriX Therapeutics raised?
BiVictriX Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did BiVictriX Therapeutics last raise money?
BiVictriX Therapeutics's most recent round on record is a Seed, in Jul 2019.
What does BiVictriX Therapeutics do?
BiVictriX Therapeutics is a biotechnology company.
Where is BiVictriX Therapeutics headquartered?
BiVictriX Therapeutics is headquartered in Cheshire, UK.
Which VCs invest in companies like BiVictriX Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at BiVictriX Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like BiVictriX Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.